AnGes, Inc.
4563・Growth Market・Pharmaceuticals
AnGes, Inc.4563
AnGes, Inc.4563
Reference Indicators
Market Cap
190¥100M
P/E (Forecast)
—
P/B
6.3x
Dividend Yield (Forecast)
0.00%
ROE
174.7%
EV/EBITDA
—
Financial Summary
Unit: ¥M
| Item | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 |
|---|---|---|---|---|---|
Net Sales | 64 | 67 | 152 | 643 | 874 |
Cost of Sales | 56 | 93 | 133 | 395 | 553 |
Gross Profit | 7 | -26 | 19 | 247 | 320 |
SG&A Expenses | 4,855 | 5,290 | 5,814 | 5,573 | 1,912 |
Operating Income | -15,632 | -16,316 | -11,967 | -9,109 | -5,145 |
Non-operating Income | 2,141 | 1,733 | 6,336 | 1,630 | 129 |
Non-operating Expenses | 97 | 26 | 20 | 58 | 272 |
Ordinary Income | -13,588 | -14,610 | -5,651 | -7,537 | -5,288 |
Extraordinary Income | 32 | 3 | 3 | 6 | 52 |
Extraordinary Losses | 179 | 110 | 1,823 | 20,112 | — |
Pre-tax Income | -13,735 | -14,716 | -7,471 | -27,643 | -5,236 |
Income Taxes | -59 | -2 | -33 | 485 | -113 |
Net Income | -13,675 | -14,714 | -7,437 | -28,128 | -5,123 |
EBITDA | -13,206 | -13,414 | -8,858 | -5,737 | -5,091 |
Gross Margin | 11.6% | -40.0% | 12.7% | 38.5% | 36.7% |
Operating Margin | -24368.8% | -24331.3% | -7822.7% | -1415.3% | -588.6% |
ROA | -30.1% | -37.9% | -25.7% | -602.5% | -94.8% |
ROE | -37.4% | -57.8% | -37.0% | 748.9% | 174.7% |
Segment Performance
Unit: ¥M
2026
| Segment | Net Sales | Operating Income | Operating Margin |
|---|---|---|---|
| 医薬品事業 | 0 | 0 | 0.0% |